ABAgnes P. Biju

Agnes P. Biju

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Agnes P. Biju has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    [18F]Flortaucipir binding and affinity to tau protein measured in postmortem human brains of Alzheimers disease and Down syndrome by autoradiography: Comparison with [ 18 F]MK-6240

    by Agnes P Biju, Josie M Herrera, Chloe C McNamara, Emma Lynn M Hipolito, Christopher Liang, Jogeshwar Mukherjee

    Flortaucipir and MK-6240 are two tau imaging agents currently in use for measuring neurofibrillary tangle (NFT) progression in Alzheimers disease (AD). The aims of this study were to use postmortem AD and Down syndrome (DS) brain sections to study three issues: (1) Measure binding affinity of flortaucipir and MK-6240 in AD brain sections by using [125I]IPPI; (2) Evaluate the binding characteristics of [18F]flortaucipir in AD, DS and cognitively normal (CN) brains sections and compare them with [18F]MK-6240, and (3) Assess the binding of [18F]flortaucipir in CN and Parkinsons disease (PD) brain sections to identify any off-target binding. The half-maximal inhibition (IC50) of [125I]IPPI bound to anterior cingulate (AC) in AD brain sections for flortaucipir was 2.91 nM and MK-6240 was 5.99 nM. Using frontal cortex (FCX) and temporal cortex (TCX) of AD, DS and CN brain sections, [18F]flortaucipir displayed high levels of binding in the gray matter (GM) of AD and DS. The average ratio of DSAD GM to CN GM was 15.7 in FCX, while DSAD GM to CN GM was 15.2 for the TCX. In the case of AD, average ratio of AD GM to CN GM was 12.4 in FCX, while AD GM to CN GM was 9.5 for the TCX. Binding of [18F]flortaucipir in brain section of AC from CN and PD cases did not exhibit any off-target binding to monoamine oxidase-A (MAO-A). In summary, both flortaucipir and MK-6240 exhibit similar high affinity to tau and [18F]flortaucipir exhibits higher binding compared to [18F]MK-6240 in DSAD.

  • Open Access

    Evaluation of [18F]MK-6240 binding to tau protein in postmortem human brains of Down syndrome and Alzheimer’s disease and assessment of off-target (non-tau) binding

    by Fariha Karim, Agnes P. Biju, Christopher Liang, Camryn J. Santos, Maharishi Rajarethenam, Jogeshwar Mukherjee

    Alzheimer's disease (AD) and Down Syndrome (DS) are characterized by the aggregation of tau tangles. As a novel tau PET tracer in AD, [ 18 F]MK-6240 has the potential in Down syndrome-associated Alzheimer’s disease (DSAD) to elucidate pathophysiology and advance diagnostic strategies. Autoradiography of frontal cortex and temporal cortex postmortem brain slices of DSAD (n = 5), AD (n = 5), and cognitively normal (CN) (n = 5) cases indicated similarly high [ 18 F]MK-6240 binding in DSAD and AD cases. [ 18 F]MK-6240 binding in CN was substantially less than DSAD and AD. Anti-tau immunostains confirmed total tau presence that aligned with the localization of [ 18 F]MK-6240 binding. DSAD and AD cases exhibited higher gray matter (GM)/white matter ratios of 2.8 and 2.5 respectively. For drug effects on [ 18 F]MK-6240 binding, self-displacement by MK-6240 (10 µM) reduced binding by 88% among DSAD cases and 85% among AD cases while IPPI (10 µM) displaced [ 18 F]MK-6240 by 81% and 74% in DSAD and AD cases respectively. KuFal194 (10 µM), a specific phosphokinase inhibitor, minimally displaced [ 18 F]MK-6240 binding. Harmine competed with [ 18 F]MK-6240 with an IC 50 value of 290 nM and 92 nM for DSAD and AD cases, respectively. High meninges off-target (non-tau) binding of [ 18 F]MK-6240 was observed in a CN case, comparable to the GM in DSAD and AD. MK-6240 (10 µM) blocked 44% and T807 (10 µM) blocked 30% of meninges binding. Incubation of meninges in the presence of 0.2% polyethyleneimine reduced 70% of [ 18 F]MK-6240 binding. The tau radioligand, [ 125 I]IPPI, an analog of [ 18 F]MK-6240, exhibited minimal binding to CN meninges compared to the DSAD and AD cases. Our findings suggest [ 18 F]MK-6240 to be selective tau imaging agent in DSAD and AD, harmine to uniquely compete with [ 18 F]MK-6240 binding in DSAD and provide preliminary insights to the off-target nonspecific binding of [ 18 F]MK-6240 in postmortem meninges.


  • Open Access

    Measurement of tau protein and Aβ amyloid plaques in postmortem human brains of Down syndrome and Alzheimer’s disease by using [ 125 I]IPPI and [ 125 I]IBETA autoradiography

    by Agnes P. Biju, Fariha Karim, Deanna M. Schafer, Stephanie A. Sison, Christopher Liang, Elizabeth Head, Jogeshwar Mukherjee

    The accumulation of tau tangles and Aβ plaques are prominent neuropathologies that characterize Alzheimer’s disease (AD) and Down Syndrome (DS). Continuous developments of PET tracers as biomarkers can be supported by autoradiography to validate effectiveness and accuracy of binding properties that elucidate the pathophysiology of DSAD and AD. This in vitro comparative study evaluates [ 125 I]IPPI binding to tau and [ 125 I]IBETA binding to Aβ plaques in the frontal cortex (FCX) and temporal cortex (TCX) of postmortem human brain slices of AD (n=5), DSAD (n=5), and cognitively normal (CN) (n=5) cases. With anti-tau and anti-Aβ immunostains confirming the presence of tau and Aβ plaques, [ 125 I]IPPI and [ 125 I]IBETA binding in autoradiographic images were significantly higher in DSAD and AD gray matter (GM) compared to CN. When comparing DSAD with AD, FCX and TCX GM binding was similar throughout DSAD and AD except in FCX GM where there was 48% more [ 125 I]IPPI binding in DSAD than AD. In vitro drug inhibition studies revealed that [ 125 I]IPPI binding was significantly inhibited with increasing harmine concentrations (IC 50 =115±40 nM) in DSAD FCX and TCX but KuFal194 minimally inhibited [ 125 I]IPPI binding in the same cases. The GM/white matter ratios for DSAD ([ 125 I]IPPI=4.1, [ 125 I]IBETA=2.9) and AD ([ 125 I]IPPI=4.2, [ 125 I]IBETA=2.6) were significantly greater than CN ([ 125 I]IPPI=1.3, [ 125 I]IBETA=1.2). A positive correlation between [ 125 I]IPPI and [ 125 I]IBETA binding suggests a synergistic relationship between tau and Aβ plaque in DSAD and AD pathology. This study demonstrates that [ 125 I]IPPI and [ 125 I]IBETA may serve as novel radiotracers in both DSAD and AD to continue diagnostic investigations in vivo.

  • Open Access

    Evaluation of [18F]MK-6240 binding to tau protein in postmortem human brains of Down syndrome and Alzheimer’s disease and assessment of off-target (non-tau) binding

    by Fariha Karim, Agnes P. Biju, Christopher Liang, Camryn J. Santos, Maharishi Rajarethenam, Jogeshwar Mukherjee

    Alzheimer's disease (AD) and Down Syndrome (DS) are characterized by the aggregation of tau tangles. As a novel tau PET tracer in AD, [ 18 F]MK-6240 has the potential in DSAD to elucidate pathophysiology and advance diagnostic strategies. Autoradiography of frontal cortex (FCX) and temporal cortex (TCX) postmortem brain slices of DSAD (n = 5), AD (n = 5), and cognitively normal (CN) (n = 5) cases indicated similarly high [ 18 F]MK-6240 binding in DSAD and AD cases. Anti-tau immunostains confirmed total tau presence so there was alignment in anti-tau abundance with quantification of [ 18 F]MK-6240 binding. DSAD and AD cases exhibited higher gray matter (GM)/white matter (WM) ratios of 2.8 and 2.5 respectively. For drug effects on [ 18 F]MK-6240 binding, self-displacement of [ 18 F]MK-6240 was by 88% among DSAD cases and 85% among AD cases while IPPI displaced [ 18 F]MK-6240 by 81% and 74% in DSAD and AD cases respectively. KuFal194, a specific phosphokinase inhibitor, minimally displaced [ 18 F]MK-6240 binding. Harmine competed with [ 18 F]MK-6240 with an IC 50 value of 290 ± 218 nM and 92 ± 15 nM for DSAD and AD cases, respectively, suggesting unique tau binding. High meninges off-target (non-tau) binding of [ 18 F]MK-6240 was observed in a CN case, comparable to the GM in DSAD and AD. MK-6240 (10 µM) blocked 44% and T807 (10 µM) blocked 30% of meninges binding. Incubation of meninges in the presence of 0.2% polyethylenimine reduced 70% of [ 18 F]MK-6240 binding. The tau imaging agent, [ 125 I]IPPI, an analog of [ 18 F]MK-6240, exhibited minimal binding to CN meninges. Our findings suggest [ 18 F]MK-6240 to be selective tau imaging agent in DSAD and AD, harmine to be a weak tau drug, and off-target nonspecific meninges binding maybe due to the primary aromatic amine group in [ 18 F]MK-6240.

  • Open Access

    Towards Imaging Tau Hyperphosphorylation: Is DYRK1A a Potential Target for Imaging Hyperphosphorylation of Tau? Molecular Modeling Assessment and Synthesis of [125I]Radioiodinated DYRK1A Inhibitor

    by Cayz G. Paclibar, Deanna M. Schafer, Agnes P. Biju, Fariha Karim, Stephanie A. Sison, Christopher Liang, Shamiha T. Ahmed, Jogeshwar Mukherjee

    Dual specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A), a phosphorylation kinase, is localized within the central nervous system and is linked to hyperphosphorylation of Tau. Imaging of DYRK1A may provide an earlier biomarker for Tauopathies, including Alzheimer’s disease (AD). We have used Chimera-Autodock to evaluate potential molecules for binding to the binding site of DYRK1A. Five molecules, 10-bromo-2-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acid (4E3), 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acid (KuFal184), harmine, 6-(fluoro-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine (MK-6240), and 6-iodo-3-(1H-pyrrolo[2,3-c]pyridine-1-yl)isoquinoline (IPPI), were found to have binding energies of −10.4, −10.1, −9.0, −9.1, and −9.4 kcal/mole, respectively. Two molecules, 4E3 and KuFal184, were selective for DYRK1A, while harmine also had a monoamine oxidase A affinity, and MK-6240 and IPPI had affinity for Tau. Tau present in the brain slices of AD subject were labeled with [125I]IPPI. KuFal184 had no effect on the binding of [125I]IPPI, suggesting the absence of binding overlap of the two molecules. MK-6240, a known Tau agent was, however, able to compete with [125I]IPPI. The binding energies of harmine, MK-6240, and IPPI for the DYRK1A site suggest affinities of approximately 80–100 nM, which is insufficient to serve as an imaging agent. The higher affinity of KuFal184 (6 nM for DYRK1A) suggested that [125I]KuFal184 may be a potential imaging agent. Electrophilic radioiodination was used to synthesize [125I]KuFal184 in modest yields (25%) and high radiochemical purity (>95%). Preliminary binding studies with [125I]KuFal184 in AD brain slices showed some selectivity for cortical grey matter regions containing Tau.


  • Open Access

    [125I]IPC-Lecanemab: Synthesis and Evaluation of Aβ-Plaque-Binding Antibody and Comparison with Small-Molecule [18F]Flotaza and [125I]IBETA in Postmortem Human Alzheimer’s Disease

    by Christopher Liang, Cayz G. Paclibar, Noresa L. Gonzaga, Stephanie A. Sison, Harman S. Bath, Agnes P. Biju, Jogeshwar Mukherjee

    Therapeutic antibodies for reducing Aβ plaque load in Alzheimer’s disease (AD) is currently making rapid progress. The diagnostic imaging of Aβ plaque load in AD has been underway and is now used in clinical studies. Here, we report our preliminary findings on imaging a therapeutic antibody, Lecanemab, in a postmortem AD brain anterior cingulate. [125I]5-iodo-3-pyridinecarboxamido-Lecanemab ([125I]IPC-Lecanemab) was prepared by coupling N-succinimidyl-5-([125I]iodo)-3-pyridinecarboxylate with Lecanemab in modest yields. The distinct binding of [125I]IPC-Lecanemab to Aβ-rich regions in postmortem human AD brains was higher in grey matter (GM) containing Aβ plaques compared to white matter (WM) (GM/WM was 1.6). Anti-Aβ immunostaining was correlated with [125I]IPC-Lecanemab regional binding in the postmortem AD human brains. [125I]IPC-Lecanemab binding was consistent with the binding of Aβ small molecules, [18F]flotaza and [125I]IBETA, in the same subjects. [18F]Flotaza and [125I]IBETA, however, exhibited significantly higher GM/WM ratios (>20) compared to [125I]IPC-Lecanemab. Our results suggest that radiolabeled [125I]IPC-Lecanemab retains the ability to bind to Aβ in human AD and may therefore be useful as a PET imaging radiotracer when labeled as [124I]IPC-Lecanemab. The ability to directly visualize in vivo a promising therapeutic antibody for AD may be useful in treatment planning and dosing and could be complimentary to small-molecule diagnostic imaging to assess outcomes of therapeutic interventions.


  • Open Access

    Glutamate’s Effects on the N-Methyl-D-Aspartate (NMDA) Receptor Ion Channel in Alzheimer’s Disease Brain: Challenges for PET Radiotracer Development for Imaging the NMDA Ion Channel

    by Nehal M. Shah, Nane Ghazaryan, Noresa L. Gonzaga, Cayz G. Paclibar, Agnes P. Biju, Christopher Liang, Jogeshwar Mukherjee

    In an effort to further understand the challenges facing in vivo imaging probe development for the N-methyl-D-aspartate (NMDA) receptor ion channel, we have evaluated the effect of glutamate on the Alzheimer’s disease (AD) brain. Human post-mortem AD brain slices of the frontal cortex and anterior cingulate were incubated with [3H]MK-801 and adjacent sections were tested for Aβ and Tau. The binding of [3H]MK-801 was measured in the absence and presence of glutamate and glycine. Increased [3H]MK-801 binding in AD brains was observed at baseline and in the presence of glutamate, indicating a significant increase (>100%) in glutamate-induced NMDA ion channel activity in AD brains compared to cognitively normal brains. The glycine effect was lower, suggesting a decrease of the co-agonist effect of glutamate and glycine in the AD brain. Our preliminary findings suggest that the targeting of the NMDA ion channel as well as the glutamate site may be appropriate in the diagnosis and treatment of AD. However, the low baseline levels of [3H]MK-801 binding in the frontal cortex and anterior cingulate in the absence of glutamate and glycine indicate significant hurdles for in vivo imaging probe development and validation.